OncoPharm

An exciting new drug, rezatapopt, may be effective in restoring p53 activity in cancers - a possible major therapeutic breakthrough. Can colchicine treat pyrexia from tremetinib & dabrafenib use? This case series says - maybe: https://doi.org/10.1007/s00520-019-4654-2

Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer patients in now published in NEJM. We discuss the results and ponder potential future changes to treating bladder cancer in the future.

Urinary diversion surgeries: https://jamanetwork.com/journals/jamaoncology/fullarticle/2842595

We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing).

Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)

A brief discussion of the Core Communication Skills* and how to incorporate them into a chemotherapy education session.

*Rapport Building
*Agenda Setting
*Information Management
*Active Listening
*Addressing Feelings
*Common Ground

Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 targeted antibodies.